Using Test Positivity and Reported Case Rates to Estimate State-Level COVID-19 Prevalence and Seroprevalence in the United States
Preprint
Abstract
Accurate estimates of infection prevalence and seroprevalence are essential for evaluating and informing public health responses needed to address the ongoing spread of COVID-19 in the United States. A data-driven Bayesian single parameter semi-empirical model was developed and used to evaluate state-level prevalence and seroprevalence of COVID-19 using daily reported cases and test positivity ratios. COVID-19 prevalence is well-approximated by the geometric mean of the positivity rate and the reported case rate. As of December 8, 2020, we estimate nation-wide a prevalence of 1.4% [Credible Interval (CrI): 0.8%-1.9%] and a seroprevalence of 11.1% [CrI: 10.1%-12.2%], with state-level prevalence ranging from 0.3% [CrI: 0.2%-0.4%] in Maine to 3.0% [CrI: 1.1%-5.7%] in Pennsylvania, and seroprevalence from 1.4% [CrI: 1.0%-2.0%] in Maine to 22% [CrI: 18%-27%] in New York. The use of this simple and easy-to-communicate model will improve the ability to make public health decisions that effectively respond to the ongoing pandemic. Biographical Sketch of Authors: Dr. Weihsueh A. Chiu, is a professor of environmental health sciences at Texas A&M University. He is an expert in data-driven Bayesian modeling of public health related dynamical systems. Dr. Martial L. Ndeffo-Mbah, is an Assistant Professor of Epidemiology at Texas A&M University. He is an expert in mathematical and computational modeling of infectious diseases. Summary Line: Relying on reported cases and test positivity rates individually can result in incorrect inferences as to the spread of COVID-19, and public health decision-making can be improved by instead using their geometric mean as a measure of COVID-19 prevalence and transmission.Keywords
All Related Versions
- Published version: PLOS Computational Biology, 17 (9), e1009374.
This publication has 11 references indexed in Scilit:
- Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020JAMA Internal Medicine, 2021
- Estimated Incidence of Coronavirus Disease 2019 (COVID-19) Illness and Hospitalization—United States, February–September 2020Clinical Infectious Diseases, 2020
- Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional studyThe Lancet, 2020
- Substantial underestimation of SARS-CoV-2 infection in the United StatesNature Communications, 2020
- Cumulative incidence and diagnosis of SARS-CoV-2 infection in New YorkAnnals of Epidemiology, 2020
- Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020MMWR. Morbidity and Mortality Weekly Report, 2020
- State-level impact of social distancing and testing on COVID-19 in the United StatesResearch Square, 2020
- Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020medRxiv, 2020
- Estimating the effects of non-pharmaceutical interventions on COVID-19 in EuropeNature, 2020
- Inference from Iterative Simulation Using Multiple SequencesStatistical Science, 1992